查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1961262

血液檢測市場－全球產業規模、佔有率、趨勢、機會、預測：按技術、產品、地區和競爭對手分類，2021-2031年

Blood Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Product, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球血液篩檢市場預計將從 2025 年的 48.8 億美元成長到 2031 年的 67.6 億美元，複合年成長率為 5.57%。

該市場涵蓋輸血前對捐血血漿和血液的嚴格檢測，以檢測傳染性病原體並確認其適用性。推動這一市場擴張的關鍵因素包括輸血傳染病在全球範圍內的日益蔓延以及強制執行安全通訊協定的嚴格監管要求。此外，創傷和外科手術治療中對血液製品的需求不斷成長，也顯著推動了更廣泛的醫療保健網路對充足篩檢能力的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 48.8億美元
市場規模：2031年 67.6億美元
複合年成長率：2026-2031年 5.57%
成長最快的細分市場 試劑
最大的市場 北美洲

另一方面，先進分子檢測平台的高成本對發展中地區預算緊張的醫療系統而言構成了一道進入門檻。儘管高階篩檢技術已被證實具有安全性優勢，但此經濟障礙限制了其應用。根據血液與生物療法促進協會2025年3月發布的報告，2023年美國採集了1,158萬單位紅血球，凸顯了已開發市場維持血液供應所需的龐大營運規模和巨額資金投入。

市場促進因素

慢性病和感染疾病的蔓延是血液篩檢市場的主要驅動力，需要嚴格的病原體鑑定以確保輸血安全。隨著全球病毒量的上升，醫療基礎設施亟需實施嚴格的核酸增幅檢查(NAT) 和免疫檢測，以便在乙型肝炎、丙型肝炎和愛滋病毒進入血液供應之前將其檢測出來。這些疾病死亡率的上升凸顯了這項需求。世界衛生組織 (WHO) 於 2024 年 4 月發布的《2024 年全球肝炎報告》顯示，2022 年病毒性肝炎導致 130 萬人死亡，這進一步強調了提高篩檢能力以遏制透過血液製品傳播疾病的緊迫性。

此外，全球對輸血和捐血的需求不斷成長，進一步加劇了市場對高效能、大容量篩檢系統的依賴，尤其是在捐血數量波動的情況下。為了最佳化每一單位採集血液的使用，需要採用自動化系統，以最大限度地減少浪費，並為緊急情況提供快速檢測結果。然而，維持充足的血液庫存仍然是一項重大挑戰。美國紅十字會在2024年1月的新聞稿中指出，過去20年捐血人數減少了約40%，凸顯了精準篩檢以避免浪費的重要性。羅氏公司在2024年報告稱，該公司前一年在全球範圍內提供了290億次診斷測試，這就是一個說明診斷需求規模的例子。

市場挑戰

先進分子檢測系統的高昂成本是全球血液篩檢市場的主要阻礙因素，尤其是在新興市場對經濟較為敏感的醫療保健領域。這些飆升的營運成本構成了准入壁壘，阻礙了已開發國家已成為標準做法的高品質篩檢技術的廣泛應用。因此，資源匱乏地區的檢查室往往依賴更便宜但過時的檢測技術，甚至完全放棄全面的篩檢。這種經濟差距直接阻礙了市場發展，限制了自動化設備和先進檢測套組的潛在基本客群，實際上將商機限制在了成熟、富裕的醫療保健網路手中。

根據國際輸血協會（ISBT）2024年的數據，由於基礎建設和資金嚴重不足，撒哈拉以南非洲地區約有20%的捐血未接受傳染病檢查。這一數字凸顯了成本障礙的嚴重後果，顯示缺乏關鍵篩檢通訊協定的資金，導致全球很大一部分人口無法獲得先進的血液安全保障。只要這些資金限制持續存在，發展中地區的市場成長將持續受到嚴重限制。

市場趨勢

擴展血型基因分型技術的興起正在重塑市場格局，其提供的捐血匹配比標準的ABO和Rh血型相容性檢測更為精準。這項發展對於避免需要長期輸血的患者（例如鐮狀細胞貧血症患者）發生同種免疫反應至關重要，因為它能夠檢測到傳統血清學檢測通常無法發現的微小抗原突變。隨著檢查室越來越重視輸血安全以減少不利事件，對先進分子分型工具的需求正在迅速成長。例如，Griffols公司在2025年2月公佈，其2024年全年銷售額成長了10.3%（不計外匯波動的影響），並特別指出其血型分型解決方案業務是關鍵市場實現兩位數成長的主要貢獻者。

同時，自動化、高通量篩檢系統正成為一個明顯的趨勢，旨在最佳化檢測流程並應對日益成長的檢測工作量。透過將檢體製備到結果解讀等各個檢測階段整合到一個整合的模組化平台中，血站可以顯著減少人為錯誤和運作成本，同時縮短週轉時間。處理大量常規檢體的中心實驗室對擴充性技術的需求進一步推動了這一趨勢。根據羅氏於2025年1月發布的2024會計年度年度報告，診斷部門的銷售額成長了4%，這主要得益於全球範圍內高通量分子和免疫診斷解決方案的廣泛應用，這些解決方案顯著提高了檢查室效率。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球血液檢測市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依技術分類（核酸增幅檢查（NAT）、酵素連結免疫吸附試驗（ELISA）、化學化學冷光免疫檢測（CLIA）、酵素免疫分析法（EIA）、次世代定序（NGS）、蛋白質印跡法）
    • 依產品（試劑、儀器）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美血液檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲血液檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區血液檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲血液檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲血液檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球血液檢測市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott
  • Roche Diagnostics
  • Bio-Rad
  • Siemens Healthineers
  • Grifols
  • Ortho Clinical Diagnostics
  • QuidelOrtho
  • Thermo Fisher
  • DiaSorin
  • Beckman Coulter

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23223

The Global Blood Screening Market is projected to expand from USD 4.88 Billion in 2025 to USD 6.76 Billion by 2031, registering a CAGR of 5.57%. This market involves the rigorous examination of donated plasma and blood to detect infectious agents and verify compatibility prior to transfusion procedures. The primary drivers for this expansion include the rising worldwide prevalence of infections transmissible via transfusion and stringent regulatory requirements that enforce safety protocols. Additionally, the growing necessity for blood products in trauma and surgical care significantly fuels the need for substantial screening capacities across extensive healthcare networks.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.88 Billion
Market Size 2031USD 6.76 Billion
CAGR 2026-20315.57%
Fastest Growing SegmentReagent
Largest MarketNorth America

Conversely, the high costs linked to sophisticated molecular testing platforms present an entry barrier for budget-constrained healthcare systems in developing areas. This financial obstacle restricts the uptake of high-end screening technologies, notwithstanding their demonstrated safety advantages. According to the Association for the Advancement of Blood & Biotherapies in March 2025, 11.58 million units of red blood cells were collected in the United States in 2023, highlighting the massive operational magnitude and financial investment necessary to maintain the blood supply in advanced markets.

Market Driver

The escalating prevalence of chronic and infectious diseases serves as a major stimulant for the blood screening market, requiring strict pathogen identification to guarantee transfusion security. With viral loads rising globally, healthcare infrastructures are urged to adopt rigorous nucleic acid amplification testing (NAT) and immunoassay measures to detect Hepatitis B, Hepatitis C, and HIV prior to their entry into the blood supply. This necessity is emphasized by increasing mortality rates linked to these conditions; according to the World Health Organization's 'Global Hepatitis Report 2024' released in April 2024, viral hepatitis caused 1.3 million deaths in 2022, reinforcing the urgent need for superior screening capabilities to curb transmission via blood products.

Furthermore, the surging global requirement for blood transfusions and donations intensifies the market's dependence on efficient, high-volume screening systems, especially given the fluctuations in donor availability. The imperative to optimize every collected unit promotes the use of automated systems that minimize discard rates and facilitate quick results for emergency cases. However, sustaining sufficient stock remains a major hurdle; the American Red Cross reported in a January 2024 press release that donor numbers have dropped by roughly 40% over the past two decades, leading to a supply crisis that underscores the value of precise screening to avoid waste. To illustrate the scale of diagnostic needs, Roche reported in 2024 that it delivered 29 billion diagnostic tests globally during the previous year.

Market Challenge

The significant costs attached to advanced molecular testing systems act as a major constraint on the Global Blood Screening Market, especially within economically sensitive healthcare sectors in emerging markets. These elevated operational expenses form a substantial barrier to entry, hindering the broad implementation of premium screening technologies that are standard practice in developed countries. As a result, laboratories in resource-poor environments frequently depend on cheaper, outdated testing techniques or skip comprehensive screening altogether. This economic gap directly impedes market progress by restricting the potential customer base for automated instruments and advanced assay kits, effectively limiting revenue opportunities to established, affluent healthcare networks.

Data from the International Society of Blood Transfusion in 2024 revealed that roughly 20% of blood donations in Sub-Saharan Africa went untested for transfusion-transmissible infections due to critical infrastructure and financial limitations. This figure highlights the severe consequences of cost barriers, as the lack of funding for vital screening protocols excludes a large segment of the global population from accessing advanced blood safety measures. As long as these financial constraints continue, the market's growth into developing regions will remain significantly restricted.

Market Trends

The rise of extended blood group genotyping is reshaping the market by facilitating exact donor-recipient matching that exceeds standard ABO and Rh compatibility checks. This evolution is vital for averting alloimmunization in patients requiring chronic transfusions, such as those suffering from sickle cell disease, by detecting minor antigen variations that conventional serology frequently fails to identify. As labs increasingly focus on transfusion safety to reduce adverse events, the demand for sophisticated molecular typing tools has risen sharply. For instance, Grifols reported in February 2025 that it achieved a 10.3% total annual revenue increase at constant currency for 2024, specifically citing its Blood Typing Solutions division as a key contributor with double-digit growth in major markets.

Simultaneously, there is a clear movement toward automated, high-throughput screening systems aimed at optimizing laboratory workflows and handling growing testing loads. By consolidating various assay stages-from sample prep to result interpretation-into unified modular platforms, blood centers can drastically cut manual errors and operating expenses while enhancing turnaround speeds. This trend is reinforced by the necessity for scalable technologies in centralized testing hubs that handle immense volumes of daily samples. According to Roche's 'Annual Report 2024' released in January 2025, Diagnostics Division sales grew by 4%, largely fueled by the robust global adoption of high-throughput molecular and immunodiagnostic solutions that improve lab efficiency.

Key Market Players

  • Abbott
  • Roche Diagnostics
  • Bio-Rad
  • Siemens Healthineers
  • Grifols
  • Ortho Clinical Diagnostics
  • QuidelOrtho
  • Thermo Fisher
  • DiaSorin
  • Beckman Coulter

Report Scope

In this report, the Global Blood Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Blood Screening Market, By Technology

  • Nucleic Acid Amplification Test (NAT)
  • ELISA
  • Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
  • Next Generation Sequencing (NGS)
  • Western Blotting

Blood Screening Market, By Product

  • Reagent
  • Instrument

Blood Screening Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Blood Screening Market.

Available Customizations:

Global Blood Screening Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Blood Screening Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (Nucleic Acid Amplification Test (NAT), ELISA, Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA), Next Generation Sequencing (NGS), Western Blotting)
    • 5.2.2. By Product (Reagent, Instrument)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Blood Screening Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Product
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Blood Screening Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By Product
    • 6.3.2. Canada Blood Screening Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By Product
    • 6.3.3. Mexico Blood Screening Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By Product

7. Europe Blood Screening Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Product
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Blood Screening Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Product
    • 7.3.2. France Blood Screening Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Product
    • 7.3.3. United Kingdom Blood Screening Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Product
    • 7.3.4. Italy Blood Screening Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By Product
    • 7.3.5. Spain Blood Screening Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By Product

8. Asia Pacific Blood Screening Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Product
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Blood Screening Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Product
    • 8.3.2. India Blood Screening Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Product
    • 8.3.3. Japan Blood Screening Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Product
    • 8.3.4. South Korea Blood Screening Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By Product
    • 8.3.5. Australia Blood Screening Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By Product

9. Middle East & Africa Blood Screening Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Product
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Blood Screening Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Product
    • 9.3.2. UAE Blood Screening Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Product
    • 9.3.3. South Africa Blood Screening Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Product

10. South America Blood Screening Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Product
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Blood Screening Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By Product
    • 10.3.2. Colombia Blood Screening Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By Product
    • 10.3.3. Argentina Blood Screening Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By Product

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Blood Screening Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Roche Diagnostics
  • 15.3. Bio-Rad
  • 15.4. Siemens Healthineers
  • 15.5. Grifols
  • 15.6. Ortho Clinical Diagnostics
  • 15.7. QuidelOrtho
  • 15.8. Thermo Fisher
  • 15.9. DiaSorin
  • 15.10. Beckman Coulter

16. Strategic Recommendations

17. About Us & Disclaimer